AdvisorShares Pure US Cannabis ETF

Trump's Executive Order Prompts U.S. Cannabis Policy Changes, Boosting Market Sentiment

US Justice Department Reschedules Marijuana to Schedule III

Trump May Re-Classify Marijuana Regulatory Status

SynBiotic SE Announces Strategy for the Developing Cannabis Market

Pure US Cannabis ETF (IIP) Releases Q2 Performance

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

TCNNF

TLRY

CURLF

CRON

GTBIF

MSOS

A new report from the Global Cannabis Network Collective and Whitney Economics highlights pricing compression as a key indicator of cannabis market maturity. It analyzes how expanding supply and evolving regulations impact pricing across emerging markets in Europe and Latin America. The report emphasizes that while initial market prices may be high, sustained downward pressure is common as markets mature. It also discusses the influence of regulatory frameworks and consumer behavior on pricing stability and operator profitability, providing insights for investors and policymakers.

prnewswire

Trulieve Cannabis Corp.

Tilray Brands

Aurora Cannabis

Curaleaf Holdings, Inc.

Canopy Growth

Cronos

Green Thumb Industries Inc.

Amplify Alternative Harvest ETF

07:05 ETNew Global Cannabis Report from GCNC and Whitney Economics Examines How Pricing Compression Reshapes Emerging Markets

CRLBF

IIPR

VICE

The recent rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act marks a significant regulatory shift for the U.S. cannabis industry. CEOs from major cannabis companies highlight key implications for investors, including improved cash flow, better access to banking services, potential uplisting on exchanges, and increased interest from institutional investors. However, there are concerns about overly optimistic timelines for recreational cannabis rescheduling, as support for such changes remains limited.

CabotWealthNetwork

Cresco Labs Inc.

Innovative Industrial Properties

AdvisorShares Vice - ETF

Here’s What “Rescheduling” Really Means for Investors

Curaleaf Holdings has opened two new medical dispensaries in Jacksonville Beach and Fernandina Beach, increasing its Florida locations to 73 and total nationwide stores to 165. CEO Boris Jordan stated that this expansion aligns with their strategy to enhance their presence in the medical cannabis market, allowing for better localized product offerings and patient-focused services across Florida.

fidelity

Curaleaf Holdings Opens Two New Stores in Florida

Curaleaf Holdings, Inc. has announced the replacement of its independent auditor PKF O’Connor Davies with BDO USA, effective May 6, 2026. This change follows an unqualified audit history, indicating it is a routine governance step rather than a response to any accounting issues. The transition is documented under Canadian continuous disclosure rules, emphasizing continuity in financial oversight. Analysts rate CURA stock as a Buy with a C$5.00 price target, while Spark's AI Analyst gives it a Neutral rating due to ongoing net losses and leverage concerns.

Tip Ranks

Curaleaf Replaces PKF O’Connor Davies with BDO USA as Independent Auditor

Curaleaf Bolsters Florida Footprint with Two New Medical Dispensaries in Jacksonville Beach and Fernandina Beach | CURLF Stock News

StockTitan

Curaleaf Bolsters Florida Footprint with Two New Medical Dispensaries in Jacksonville Beach and Fernandina Beach | CURLF Stock News

Curaleaf Holdings, Inc. reported its first quarter 2026 results, showcasing a net revenue of $324 million, a 6% increase year-over-year. The company achieved a gross profit margin of 49% and net income of $70 million. Curaleaf expanded its retail presence, opening new dispensaries in Florida and Maine, and launched new products. The company also completed the buyout of its German subsidiary, Four 20 Pharma, increasing its ownership to 100%. Curaleaf's CEO highlighted the positive shift in the cannabis industry due to recent regulatory changes, positioning the company for future growth.

16:01 ETCuraleaf Reports First Quarter 2026 Results: Robust Growth and Net Income

Curaleaf Holdings has acquired the remaining 45% stake in Germany's Four 20 Pharma, achieving full ownership of the medical cannabis producer. This move strengthens Curaleaf's European operations and enhances its supply chain from Portugal and Canada into Germany. The acquisition aims to improve patient access to medical cannabis and solidify Curaleaf's position in the regulated cannabis market. Analysts rate CURA stock as a Buy with a price target of C$5.50, although concerns about profitability and margin pressure persist.

Curaleaf Takes Full Control of Germany’s Four 20 Pharma to Bolster European Cannabis Platform

Curaleaf Holdings, Inc. filed a Form 6-K with the SEC, reporting unaudited interim financials for Q1 2026. The filing includes financial statements as of March 31, 2026, and management's analysis, ensuring compliance and transparency. The latest analyst rating for CURA stock is a Buy with a C$5.50 price target, while Spark's AI Analyst rates it as Neutral, citing improving cash flow but weak underlying profitability. Curaleaf operates in the cannabis sector, registered with the SEC, and has a market cap of C$3.45B.

Curaleaf Files Q1 2026 Interim Financials on Form 6-K

Curaleaf Holdings has scheduled its virtual Annual and Special Meeting for June 22, 2026, with a record date of May 5, 2026, for voting shareholders. The agenda includes director elections, auditor appointments, and a proposal to amend the multiple voting share structure. Additionally, shareholders will vote on a plan to redomicile the company from British Columbia to Delaware. The latest analyst rating for Curaleaf stock (TSE:CURA) is a Buy with a C$5.50 price target, although profitability concerns persist.

Curaleaf Sets June 22 Virtual Shareholder Meeting to Vote on Governance, Equity Plan and Delaware Move

WEED

CNBS

YOLO

President Trump announced plans to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act, providing a boost to cannabis stocks that have faced significant losses over the past five years. This announcement follows an executive order aimed at increasing funding and research for psilocybin and other substances.

Roundhill Cannabis ETF

Amplify Seymour Cannabis ETF

AdvisorShares Pure Cannabis ETF

Trump's rescheduling of marijuana is a spark for top marijuana ETFs

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: U.S. Reclassifies Medical Marijuana to Schedule III - AP$Tilray Brands(TLRY.US) $SNDL(SNDL.US) $Organigram(OGI.US) $AdvisorShares Pure US Cannabis ETF(MSOS.US) $TRUL $Aurora Cannabis(ACB.US) $Cronos(CRON.US) $Canopy Growth(CGC.US) 👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:➤ Trump administration moves medical marijuana to 𝐒𝐜𝐡𝐞𝐝𝐮𝐥𝐞 𝐈𝐈𝐈.➤ Shift reclassifies cannabis from 𝐒𝐜𝐡𝐞𝐝𝐮𝐥𝐞 𝐈 status.➤ Change applies to 𝐬𝐭𝐚𝐭𝐞-𝐥𝐢𝐜𝐞𝐧𝐬𝐞𝐝 medical marijuana operators.➤ Does not fully 𝐥𝐞𝐠𝐚𝐥𝐢𝐳𝐞 cannabis at federal level.➤ Opens door to expanded 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 and medical use.➤ Provides potential 𝐭𝐚𝐱 𝐫𝐞𝐥𝐢𝐞𝐟 for cannabis businesses.➤ Marks major shift in U.S. 𝐝𝐫𝐮𝐠 𝐩𝐨𝐥𝐢𝐜𝐲 and regulation.Source: Hardik Shah

SNDL

Organigram

NewUser_viBZF

🚨 The US cannabis sector just jumped 20% in an instant as news breaks that Trump plans to reclassify marijuana today 🌿 $AdvisorShares Pure US Cannabis ETF(MSOS.US)Source: TrendSpider

The grass is growing back 🌿 $AdvisorShares Pure US Cannabis ETF(MSOS.US)Source: TrendSpider

Some movers today up over 2.5% or more $FTAI Aviation(FTAI.US) $Ondas(ONDS.US) $AdvisorShares Pure US Cannabis ETF(MSOS.US) $AST SpaceMobile(ASTS.US) $Unusual Machines(UMAC.US) $Zeta Global(ZETA.US) $Serve Robotics(SERV.US) $Rocket Lab(RKLB.US) $Intel(INTC.US) $Rocket(RKT.US) $Patterson-UTI Energy(PTEN.US)Source: Sunrise Trader